

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

RECEIVED  
SECRETARY OF THE SENATE  
PUBLIC RECORDS

02 AUG 22 AM 10:41

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name American Pharmaceutical Association			
2. Address <input type="checkbox"/> Check if different than previously reported 2215 Constitution Avenue, NW, Washington, DC 20037			
3. Principal Place of Business (if different from line 2) City: _____ State/Zip (or Country) _____			
4. Contact Name Mary Singletary	Telephone (202) 429-7572	E-mail (optional) msingletary@aphanet.org	5. Senate ID # 3017
7. Client Name <input checked="" type="checkbox"/> Self Self			6. House ID # 31620

**TYPE OF REPORT** 8. Year 2002 Midyear (January 1-June 30)  OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇒ Termination Date \_\_\_\_\_

11. No Lobbying

### INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p align="center"><b>12. Lobbying Firms</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center"><b>13. Organizations</b></p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ <u>165,199.00</u> Expenses (nearest \$20,000)</p> <p><b>14. REPORTING METHOD.</b> Check box to indicate accounting method. See instructions for description of</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033 Internal Revenue Code</p> <p><input checked="" type="checkbox"/> Method C. Reporting amounts under section 162 Internal Revenue Code</p>
---	---

Signature \_\_\_\_\_

Printed Name and Title \_\_\_\_\_

Mary Singletary, Administrative Coordinator



Registrant Name American Pharmaceutical Association Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

Conquering Pain Act of 2001 (H.R. 2156/S. 1024)  
Medical Error Reporting and Medication Safety (H.R. 4889/S. 2590)  
Increasing Federal Support for the Indian Health Services and Tribal Health Care Programs - FY2003 Interior Appropriations  
Standards for Privacy and Individually Identifiable Health Information (65 FR 82462-82829, 12/28/00), (67 FR 14775-14815, 3/27/02)  
H.R. 3448/S. 1765: Bioterrorism Preparedness Act of 2001; Prescription Drug User Fee Re-authorization

17. House(s) of Congress and Federal agencies contacted  Check if None

U.S. Senate  
U.S. House of Representatives  
Department of Health and Human Services  
Drug Enforcement Administration

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Susan C. Winckler, RPh, JD	
Lisa M. Geiger	
Susan K. Bishop	
Mitch C. Rothholz	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature *Mary Singletary* Date 8/14/02  
Printed Name and Title Mary Singletary, Administrative Coordinator



Registrant Name American Pharmaceutical Association Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Medicare Prescription Drug Benefit (S. 2625, H.R. 4954, H.R. 3626, H.R. 4741)  
Payment for Services/Recognition of Pharmacists as Providers (S. 974, H.R. 2799)  
Administration's Medicare-endorsed Prescription Drug Discount Card


17. House(s) of Congress and Federal agencies contacted  Check if None

U.S. Senate  
U.S. House of Representatives  
Department of Health and Human Services  
White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Susan C. Winckler, RPh, JD	
Lisa M. Geiger	
Susan K. Bishop	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date 8/14/02  
Printed Name and Title Mary Singletary, Administrative Coordinator



Registrant Name American Pharmaceutical Association Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the re engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific lobbying issues

Pharmacy Education Aid Act of 2001 (H.R. 2173/S. 1806)  
Implementation of Pharmacy Compounding Regulations (FDA Modernization Act of 1997)  
H.R. 68/S. 1132. To amend the Federal Food, Drug, & Cosmetic Act re: distribution chain of prescription drugs  
Dietary Supplement Health and Education Act  
Electronic Transmission of Prescriptions  
Medguide Implementation  
Management of High Risk Medications  
Importation of Medications (S. 2244, H.R. 4614)


17. House(s) of Congress and Federal agencies contacted  Check if None

U.S. Senate  
U.S. House of Representatives  
Department of Health and Human Services  
Drug Enforcement Administration  
Food and Drug Administration

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Susan C. Winckler, RPh, JD	
Lisa M. Geiger	
Susan K. Bishop	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date 8/14/02  
Printed Name and Title Mary Singletary, Administrative Coordinator



Registrant Name American Pharmaceutical Association Client Name Self

**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

N/A

21. Client new principal place of business (if different from line 20)

City

State/Zip (or Country)

22. New general description of client's business or activities

**LOBBYIST UPDATE**

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

**ISSUE UPDATE**

24. General lobbying issues previously reported that **no longer** pertain

**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Busin (city and state or coun

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client


**FOREIGN ENTITIES**

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	C P C

28. Name of each previously reported foreign entity that **no longer** owns, or controls, or is affiliated with the registrant affiliated organization

Signature



Date

8/14/02

Printed Name and Title

Mary Singletary, Administrative Coordinator

